The mutation or overexpression of
alpha-synuclein protein plays a pivotal role in the pathogenesis of
Parkinson's disease. In our preliminary experiments, we found that
alpha-synuclein induced the expression of
matrix metalloproteinases (
MMPs) (MMP-1, -3, -8, and -9) in rat primary cultured microglia. Thus, the current study was undertaken to determine the roles of
MMPs in
alpha-synuclein-induced microglial activation. The inhibition of MMP-3, -8, or -9 significantly reduced NO and
reactive oxygen species levels and suppressed the expression of
TNF-alpha and IL-1beta. Notably, MMP-8 inhibitor suppressed
TNF-alpha production more efficaciously than MMP-3 or MMP-9 inhibitors. Inhibition of MMP-3 or -9 also suppressed the activities of MAPK,
NF-kappaB, and
AP-1. Previously,
protease-activated receptor-1 (PAR-1) has been associated with the actions of
MMPs, and thus, we further investigated the role of PAR-1 in
alpha-synuclein-induced inflammatory reactions. A PAR-1-specific inhibitor and a PAR-1 antagonist significantly suppressed
cytokine levels, and NO and
reactive oxygen species production in
alpha-synuclein-treated microglia. Subsequent PAR-1 cleavage assay revealed that MMP-3, -8, and -9, but not
alpha-synuclein, cleaved the synthetic
peptide containing conventional PAR-1 cleavage sites. These results suggest that
MMPs secreted by
alpha-synuclein-stimulated microglia activate PAR-1 and amplify microglial inflammatory signals in an autocrine or paracrine manner. Furthermore, our findings suggest that modulation of the activities of
MMPs and/or PAR-1 may provide a new therapeutic strategy for
Parkinson's disease.